# Adaptilens

> Adaptilens is a pre-clinical biotechnology company in Newton, Massachusetts developing the first biomimetic accommodating intraocular lens (A-IOL) - a soft, flexible artificial lens that responds to the eye's natural focusing signal from the ciliary muscle. Founded by ophthalmologist Dr. Liane Clamen, the company aims to replace the cataract-clouded natural lens with one that restores clear vision across near, intermediate, and distance ranges without glasses, contacts, or the halos and glare common to multifocal alternatives. Adaptilens raised a $17.5M Series A in April 2024 to advance its A-IOL toward first-in-human trials.

- **Founded:** 2019
- **Headquarters:** Newton, Massachusetts, United States
- **Founders:** Liane Clamen (Founder & CEO)
- **Team size:** ~9 employees
- **Products:** Adaptilens A-IOL (Accommodating Intraocular Lens)
- **Notable:** Developing what it describes as the first and only biomimetic accommodating intraocular lens that responds to the eye's natural focusing signal., Closed a $17.5M Series A in April 2024 led by Perceptive Xontogeny Venture Funds., Patent for the accommodating IOL granted in 2019.

## Products & services

- **Adaptilens A-IOL (Accommodating Intraocular Lens)** — A soft, flexible, biomimetic artificial lens designed to replace the natural lens during cataract surgery. It responds to the eye's natural accommodation signal from the ciliary muscle, changing shape to focus across near, intermediate, and distance ranges - aiming to avoid the halos, glare, and reduced contrast sensitivity associated with multifocal, trifocal, and EDOF lenses. Built on proprietary bottlebrush polymer materials. Currently in pre-clinical development and not yet approved for investigational or commercial use.

## Achievements

- Developing what it describes as the first and only biomimetic accommodating intraocular lens that responds to the eye's natural focusing signal.
- Closed a $17.5M Series A in April 2024 led by Perceptive Xontogeny Venture Funds.
- Patent for the accommodating IOL granted in 2019.
- Selected into MassChallenge's medical devices cohort (2020).
- Built a research partnership with Duke University around proprietary bottlebrush polymer materials.

## Latest updates

- **2024-04** — Announced the close of a $17.5M Series A financing round led by Perceptive Xontogeny Venture Funds, with Pillar VC, 380 Cap, and Accanto Partners participating, to advance the A-IOL toward first-in-human trials.

## Links

- Website: https://adaptilens.com
- LinkedIn: https://www.linkedin.com/company/adaptilens

---

Profile page: https://yespress.io/adaptilens
Published by YesPress — https://yespress.io
Last updated: 2026-06-16